Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/73959
Título: Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
Autores/as: Boronat Cortés, Mauro 
Sánchez Hernández, Rosa María 
Rodríguez-Cordero, Julia
Jiménez-Ortega, Angelines
Novoa Mogollón, Francisco 
Clasificación UNESCO: 320502 Endocrinología
Palabras clave: Therapy
Infusion
Fecha de publicación: 2015
Publicación seriada: Endocrinology, Diabetes and Metabolism Case Reports 
Resumen: Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin delivered through CSII therapy. However, even for patients treated with CSII, exaggerated postmeal hyperglycemic excursions and late postabsorptive hypoglycemia can still constitute a therapeutic challenge. Two female patients with type 1 diabetes who began treatment with CSII required to increase their previous breakfast insulin-to-carbohydrate ratio in order to achieve postprandial glycemic goals. However, they simultaneously presented recurrent episodes of late hypoglycemia several hours after breakfast bolus. Advancing the timing of the bolus was ineffective and bothersome for patients. In both cases, the best therapeutic option was to set a basal insulin rate of zero units per hour during 6 h after breakfast. Even so, they need to routinely take a midmorning snack with 10-20 g of carbohydrates to avoid late postabsorptive hypoglycemia. They have been using this insulin schedule for about 3 years without complications. The action of prandial insulin delivered through insulin pumps can be inappropriately delayed for the requirements of some patients. Although suspension of basal rate can be an acceptable therapeutic alternative for them, these cases demonstrate that new strategies to improve the bioavailability of prandial insulin infused through CSII are still needed.
URI: http://hdl.handle.net/10553/73959
ISSN: 2052-0573
DOI: 10.1530/EDM-14-0081
Fuente: Endocrinology Diabetes And Metabolism Case Reports [ISSN 2052-0573], v. 2015 (1), ID: 14-0081, (Enero 2015)
Colección:Artículos
miniatura
pdf
Adobe PDF (182,98 kB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.